BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Park J, Park S, Lee SA, Park SJ, Cheon JH. Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management. Korean J Intern Med 2021. [PMID: 34344146 DOI: 10.3904/kjim.2021.114] [Reference Citation Analysis]
2 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
3 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
4 Romero RK, Magro DO, Queiroz NSF, Damião AOMC, Teixeira FV, Nones RB, Sassaki LY, Saad-Hossne R, Kotze PG. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB). Gastroenterol Hepatol 2021:S0210-5705(21)00296-X. [PMID: 34634427 DOI: 10.1016/j.gastrohep.2021.09.005] [Reference Citation Analysis]
5 Stewart MJ, Bessissow T, Gregor J, Hazel M, In TSH, Karra K, Dajnowiec D, Williamson M, Sattin B. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis. Adv Ther 2021;38:4115-29. [PMID: 34159558 DOI: 10.1007/s12325-021-01818-3] [Reference Citation Analysis]
6 Gisbert JP, Chaparro M. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. Drugs 2020;80:1085-100. [PMID: 32562207 DOI: 10.1007/s40265-020-01346-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
7 Kakiuchi T, Yoshiura M. Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab: A case report. Medicine (Baltimore) 2022;101:e28873. [PMID: 35363198 DOI: 10.1097/MD.0000000000028873] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Veloso PM, Machado R, Nobre C. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art. Eur J Pharm Biopharm 2021;167:89-103. [PMID: 34329709 DOI: 10.1016/j.ejpb.2021.07.014] [Reference Citation Analysis]
9 Skovdahl HK, Gopalakrishnan S, Svendsen TD, Granlund AVB, Bakke I, Ginbot ZG, Thorsvik S, Flatberg A, Sporsheim B, Ostrop J, Mollnes TE, Sandvik AK, Bruland T. Patient Derived Colonoids as Drug Testing Platforms-Critical Importance of Oxygen Concentration. Front Pharmacol 2021;12:679741. [PMID: 34054553 DOI: 10.3389/fphar.2021.679741] [Reference Citation Analysis]